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Abstract
Background: Autopsy studies of HIV/AIDS-related hospital deaths in sub-Saharan Africa reveal frequent failure of
pre-mortem diagnosis of tuberculosis (TB), which is found in 34–64 % of adult cadavers. We determined the overall
prevalence and predictors of TB among consecutive unselected HIV-positive adults requiring acute hospital
admission and the comparative diagnostic yield obtained by screening urine and sputum samples obtained on day
1 of admission with Xpert MTB/RIF (Xpert).
Methods: To determine overall TB prevalence accurately, comprehensive clinical sampling (sputum, urine, blood
plus other relevant samples) was done and TB was defined by detection of Mycobacterium tuberculosis in any
sample using Xpert and/or mycobacterial liquid culture. To evaluate a rapid screening strategy, we compared the
diagnostic yield of Xpert testing sputum samples and urine samples obtained with assistance from a respiratory
study nurse in the first 24 h of admission.
Results: Unselected HIV-positive acute adult new medical admissions (n = 427) who were not receiving TB
treatment were enrolled irrespective of clinical presentation or symptom profile. From 2,391 cultures and Xpert tests
done (mean, 5.6 tests/patient) on 1,745 samples (mean, 4.1 samples/patient), TB was diagnosed in 139 patients
(median CD4 cell count, 80 cells/μL). TB prevalence was very high (32.6 %; 95 % CI, 28.1–37.2 %; 139/427). However,
patient symptoms and risk factors were poorly predictive for TB. Overall, ≥1 non-respiratory sample(s) tested
positive in 115/139 (83 %) of all TB cases, including positive blood cultures in 41/139 (29.5 %) of TB cases. In the first
24 h of admission, sputum (spot and/or induced samples) and urine were obtainable from 37.0 % and 99.5 % of
patients, respectively (P <0.001). From these, the proportions of total TB cases (n = 139) that were diagnosed by
Xpert testing sputum, urine or both sputum and urine combined within the first 24 h were 39/139 (28.1 %), 89/139
(64.0 %) and 108/139 (77.7 %) cases, respectively (P <0.001).
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Conclusions: The very high prevalence of active TB and its non-specific presentation strongly suggest the need for
routine microbiological screening for TB in all HIV-positive medical admissions in high-burden settings. The
incremental diagnostic yield from Xpert testing urine was very high and this strategy might be used to rapidly
screen new admissions, especially if sputum is difficult to obtain.
Keywords: Tuberculosis, Pulmonary, Extrapulmonary, HIV, Diagnosis, Screening, Urine, Xpert, Africa
Background
Tuberculosis (TB) is the leading cause of HIV/AIDS-related
mortality [1], accounting for approximately 37 % of HIV/
AIDS-related adult facility-based deaths in resource-limited
settings [2]. Most of these deaths occur in sub-Saharan
Africa where multiple hospital post-mortem studies con-
ducted over the past 20 years have shown that between 34
% and 64 % of HIV-positive patients had TB at the time of
death [2–7]. Disease at autopsy was predominantly dissemi-
nated and frequently remained undetected pre-mortem [2],
reflecting failure of existing approaches to screening and
TB diagnosis in HIV-infected medical in-patients.
The global TB control strategy defined in the mid-
1990s was based on passive detection of sputum smear-
positive pulmonary TB (PTB) in patients presenting with
chronic cough [8]. However, in HIV-infected patients
with TB and advanced immunodeficiency, chronic cough
is less frequent, clinical presentation is non-specific, spu-
tum smears are often negative and extrapulmonary TB
(EPTB) is common [9, 10]. We therefore hypothesized
that all HIV-positive patients requiring medical admis-
sion to hospitals in sub-Saharan Africa might warrant
systematic routine microbiological investigation for TB
regardless of clinical presentation. Second, we hypothe-
sized that useful incremental diagnostic yield might be
gained from additional testing of a non-respiratory sam-
ple such as urine, which is easier to obtain than sputum.
The advent of semi-automated rapid molecular tests
provides new effective means of diagnosing HIV-
associated TB. The Xpert MTB/RIF (Xpert) assay was
endorsed by the World Health Organization (WHO) in
2010 for diagnosis of TB from sputum [11] and guide-
lines were updated in 2013 to include TB diagnosis from
a range of non-respiratory samples, including cerebro-
spinal fluid and tissue needle aspirates/biopsies [12]. En-
dorsement was not given for testing other sample types
due either to low sensitivity (pleural fluid) or for sample
types for which there were insufficient data (stool, urine
and blood). Importantly, however, assay specificity was
found to be uniformly high regardless of sample type
[12–14]. Moreover, two studies using Xpert to test urine
samples from HIV-infected patients with advanced im-
munodeficiency each reported very promising results
with high specificity (98 % and 100 %) and useful diag-
nostic yield, especially among in-patients [15, 16].
The present study conducted in a South African dis-
trict hospital first aimed to accurately determine the
prevalence and predictors of microbiologically confirmed
TB among unselected HIV-positive medical admissions
using microbiological screening. We then planned to use
these data to define which patient sub-groups were at
highest risk of TB and might warrant routine microbio-
logical investigation at the time of hospital admission.
Finally, with the ultimate aim of defining an effective
rapid microbiological screening strategy on the first day
of hospital admission among unselected HIV-positive
admissions, we compared the diagnostic yield (propor-
tions of total diagnoses) that could be made from rapid
testing sputum and urine samples obtained in the 24-h
period following admission using Xpert MTB/RIF.
Methods
Setting and patients
A prospective observational study was conducted at GF
Jooste Hospital in Cape Town, South Africa. This 200-bed
adult district hospital serves township communities of
around 1.3 million people and with high HIV seropreva-
lence. This pre-defined study protocol was approved by
the human research ethics committees of the University of
Cape Town, South Africa, and the London School of
Hygiene & Tropical Medicine, UK. Patients provided writ-
ten informed consent in their first language.
Adult patients aged ≥18 years were recruited on 4 days
of each week from both male and female medical wards.
On recruitment days, the study coordinator ascertained
from the ward register all medical admissions in a 24-h
period and recorded these in the study register. All pa-
tients with previously negative or undocumented HIV
status were offered testing using two rapid tests. All pa-
tients with a positive test (either a new or an existing
test result) were eligible and invited to participate in the
study. Patients receiving TB treatment at the time of
hospital admission, however, were excluded.
Procedures and samples
Demographic and clinical details (including the WHO
symptom screen for HIV-associated TB [17]) were re-
corded as were medical history, use of antiretroviral
therapy (ART), TB treatment and isoniazid preventive
therapy (IPT). Patients were systematically investigated
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by the research team by obtaining sputum, urine and blood
specimens for mycobacteriology between 9.00 am on the
day of enrolment and 9.00 am the following day. Numer-
ous additional samples for mycobacteriology were re-
quested by the routine medical team as clinically indicated
during the patient’s admission. These included sputum and
a wide range of non-respiratory samples (Table 1).
In the first 24 h of admission, two sputum samples
were requested from each patient with careful instruc-
tion and supervision by the study coordinator who was a
trained respiratory nurse. A spot specimen was obtained
first followed by a second sample that was induced using
nebulized 3 % hypertonic saline. If necessary, both speci-
mens were induced. Alternatively, for patients too
unwell for sputum induction (for example, those with re-
spiratory failure, bronchospasm or other danger signs),
two spot specimens were requested instead. Urine samples
were systematically collected using single-use disposable
bed pans (Litha Healthcare Group, Johannesburg, South
Africa) and a sterile syringe was used to transfer 50 ml to
a polypropylene tube (Becton Dickinson, Sparks, MD,
USA). Fresh aliquots (2.0 ml) were sent for immediate
Xpert testing and the remaining urine was stored
at −20°C for repeat Xpert testing after defrosting and
concentration by centrifugation. Venous blood (5.0 ml)
was inoculated into BACTEC™ Myco/F Lytic culture
vials (Becton Dickinson, Franklin Lakes, NJ, USA).
Laboratory procedures
Specimens were processed using standardized protocols
and quality assurance procedures in centralized accredited
laboratories of the South African National Health Labora-
tory Service (NHLS) as described elsewhere [18, 19].
Decontaminated, centrifuged deposits of sputum samples
obtained in the first 24 h were resuspended in phosphate
buffer and equal volumes were tested using culture and
Xpert MTB/RIF. Mycobacterial growth indicator tubes
(MGIT; Becton Dickinson) were inoculated and incubated
for up to 6 weeks. Culture isolates were identified as Myco-
bacterium tuberculosis complex with the MTBDRplus line
probe assay (Hain Lifescience, Nehren, Germany).
Additional sputum samples requested by the medical
team were tested by MGIT culture and/or Xpert accord-
ing to prevailing policy. Blood cultures from all patients
were done in BACTEC™ Myco/F Lytic culture vials and
other non-respiratory samples, such as pleural fluid,
cerebrospinal fluid and tissue fine needle aspirates, were
tested using MGIT culture.
Urine was tested using Xpert in two ways. Fresh urine
samples (2.0 ml) were centrifuged and resuspended in
Table 1 Clinical samples sent for mycobacteriology
Sample Urine and sputum samples
obtained in first 24 h
Total samples obtained during admission
Number of patients
producing ≥1
sample (%)
Total
number of
samples
Number of patients
producing ≥1
sample (%)
Total
number
of samples
Total number
of culture and
Xpert tests done
Number of positive
culture and
Xpert tests (%)
Number of TB patients
with ≥1 positive culture
or Xpert test (%)
Sputum 158 (37.0) 279 245 (57.4) 615 871 210 (24.1) 75 (54.0)a
Urine 418 (97.9) 418 418 (97.9) 418 833 141 (16.9) 89 (64.0)
Other non-
respiratory samples
- - 418 (97.9) 712 687 91 (13.2) 69 (49.6)
Ascitic fluid - - 5 (1.2) 5 5 1 (20.0) 1 (0.7)
Blood - - 410 (96.0) 469 469 41 (8.7) 41 (29.5)
Bone marrow - - 2 (0.5) 2 2 0 0
Cerebrospinal
fluid (CSF)
- - 76 (17.8) 94 94 8 (8.5) 8 (5.8)
Fine needle
aspirate (FNA)
- - 19 (4.4) 23 10 6 (60.0) 6 (4.3)
Gastric lavage - - 5 (1.2) 7 7 2 (28.6) 1 (0.7)
Pus - - 5 (1.2) 6 6 4 (66.7) 3 (2.2)
Pleural fluid - - 21 (4.9) 29 29 17 (58.6) 13 (9.4)
Stoolb - - 9 (2.1) 10 0 0 0
Urinec - - 60 (14.1) 63 61 11 (18.0) 11 (7.9)
Other - - 4 (0.9) 4 4 1 (25.0) 1 (0.7)
Total 420 (98.4) 697 427 (100) 1,745 2,391 442 (18.5) 139 (100)
aOnly 39 (28.1 %) of total diagnoses could be made from sputum samples obtained in the first 24 h; btested by Ziehl–Neelsen staining only; curine samples
requested later than the first 24-h period for culture (not part of Xpert screening strategy)
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0.75 ml of phosphate buffer and then tested using the
Xpert MTB/RIF assay as previously described [15]. In
light of study-related logistical considerations and la-
boratory workflow, batches of frozen urine samples were
defrosted and tested on a weekly basis. Each urine sam-
ple of between 30 ml and 40 ml was defrosted and cen-
trifuged at 3,000 g for 15 min. Following removal of the
supernatant, the pellet was resuspended in the residual
urine volume and 0.75 ml was tested using Xpert.
Data analysis
The proportions of patients able to produce urine and/or
sputum samples during the first 24 h of admission were
calculated and compared. New TB diagnoses were defined
by detection of M. tuberculosis from any clinical sample
obtained at any time during the admission period using
MGIT culture or Xpert. The total yield of microbiologic-
ally confirmed TB diagnoses was used to calculate TB
prevalence with 95 % exact confidence intervals (95 % CI).
Then, using the total number of microbiological diagnoses
as the denominator, we calculated the comparative yield of
TB diagnoses from Xpert testing samples of urine and
sputum obtained during the initial 24 h of admission. In
addition, the proportions of patients whose TB diagnoses
were derived from testing sputum samples (pulmonary TB
(PTB)) and/or non-respiratory samples (extrapulmonary
TB (EPTB)) were compared and these data were displayed
using Venn diagrams.
Patients were characterized using simple descriptive sta-
tistics. Moderate and severe anaemia was defined using
WHO criteria (haemoglobin ≤10.9 g/dL for both males and
females) [20]. Medians were compared using either
Wilcoxon rank-sum tests or Kruskal–Wallis tests as appro-
priate and means were compared using unpaired t-tests.
Chi-squared, Fisher’s exact and McNemar’s tests were used
as appropriate to compare proportions. Logistic regression
analyses were used to identify patient factors associated
with TB diagnosis. All variables in the univariable model
meeting a cut-off of P ≤0.1 were included in the multivari-
able model. Statistical tests were two-sided at α = 0.05.
Results
Patients
Between 6th June 2012 and 4th October 2013, the HIV
status of 1,013 of 1,018 (99.5 %) unselected new admis-
sions to the adult medical wards was ascertained (Fig. 1).
Of the 609 patients who were HIV-positive, 585 (96.1 %)
were enrolled in the study and investigated for TB. Those
already receiving treatment for an existing diagnosis of TB
at the time of admission (n = 158) were excluded, leaving
427 patients eligible for inclusion. These were typically
young adults of whom a majority knew their positive HIV
status before admission and more than one half had previ-
ously started ART (Table 2). Immunodeficiency was
typically advanced and CD4 cell counts (median, 149
cells/μL) were lower among those who were ART-naive
compared to those currently receiving ART (115 cells/μL
versus 212 cells/μL; P <0.001). Two-thirds of all patients
had moderate or severe anaemia. A history of previous TB
was very common. No patients had received IPT. The vast
majority of all patients had a positive WHO TB symptom
screen regardless of TB status.
Clinical samples obtained
During hospital admission, clinical samples for mycobac-
teriology were obtained from all study participants (n =
427) with a total of 1,745 samples (average, 4.1 samples
per patient). At least two samples were obtained from all
patients except one and these samples were from a me-
dian of three anatomic locations per patient (Table 1).
In the first 24 h of admission, urine samples were pro-
duced by 425 of 427 (99.5 %) patients, although seven
samples were misplaced in transit to the laboratory, leav-
ing 418 urine samples available for testing. In contrast,
only 158 (37.0 %) patients were able to produce sputum
in the same 24-h period (P <0.001) despite assistance
from a respiratory nurse. Of these sputum samples, 37
(23.4 %) were obtained following sputum induction. The
remaining patients who did not produce sputum were
typically too sick or uncooperative to tolerate sputum in-
duction, or it was unsuccessful.
Sputum was eventually produced by a total of 245 (57.4
%) patients at some point during their admission. The abil-
ity of patients to produce sputum samples was strongly re-
lated to the presence or absence of respiratory symptoms
prior to admission. Of 161 patients who self-reported spu-
tum production prior to admission, 143 (88.8 %) were able
to produce a sputum sample for testing. Of 201 patients
reporting current cough at admission, 159 (79.1 %) pro-
duced a sputum sample. Of 34 patients with chronic cough
≥2 weeks, 27 (79.4 %) produced a sputum sample.
A large number (n = 712) of various other non-
respiratory samples were obtained (Table 1). A total of
2,391 Xpert and mycobacterial cultures were done on all
the accumulated samples collected (mean, 5.6 tests per pa-
tient). The mean number of tests was similar for patients in
whom TB was or was not diagnosed (5.8 tests versus 5.5
tests, respectively; P = 0.154). Results were missing for a
small proportion of samples: 4.3 % (n = 12) of sputum cul-
tures were contaminated; and 4.3 % (n = 12) of sputum
Xpert tests and 3.1 % (n = 26) of urine Xpert tests gave
indeterminate results.
TB prevalence and risk factors
A microbiological diagnosis of TB was made in 139 patients
(mean, 3.2 positive samples per case diagnosed) and the
characteristics of those with and without TB are summa-
rized in Table 2. The overall prevalence of TB was 32.6 %
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(95 % CI, 28.1–37.2; 139/427). Thus, the number of pa-
tients that had to be screened (number needed to screen
(NNS)) to diagnose one additional case was just 3.1 (95 %
CI, 2.7–3.6). Overall, ≥1 non-respiratory sample(s) tested
positive (indicating extrapulmonary involvement) in 115/
139 (83 %) of all TB cases, including positive blood cultures
in 41/139 (29.5 %). When patients were stratified by various
demographic or clinical characteristics or by presenting
symptoms, TB prevalence ranged from 11.1 % to 52.9 %,
and in univariable analyses was associated with younger
adults, those with a new HIV diagnosis, those who were
ART-naive, those with lower CD4 cell counts and those
with moderate or severe anaemia (Table 3). The corre-
sponding NNS in these groups ranged from 1.9 to 9.0.
We next examined the predictive value of symptoms for
identifying those with TB. Although the sensitivity of the
WHO symptom screen [17] for HIV-associated TB was
97.1 % (92.7–99.2 %), the specificity was only 11.1 % (7.8–
15.4 %) and the positive predictive value was just 34.5 %
(29.7–39.4 %). In multivariable analyses, neither a positive
WHO symptom screen nor a patient report of pre-
admission sputum production was a significant independ-
ent predictor of TB diagnosis (Table 4). In contrast, lower
CD4 cell counts and moderate and severe anaemia were in-
dependently associated with a higher risk of TB, while a his-
tory of previous treatment for TB was protective (Table 4).
Diagnostic yield from urine and sputum samples
obtained in first 24 h
With the aim of defining a day 1 rapid microbiological
screening strategy for new admissions, we next compared
the diagnostic yields of Xpert when testing whatever spu-
tum and urine samples could be obtained during the first
24 h of admission (Table 5). The number (%) of cases diag-
nosed from urine was substantially increased by prior con-
centration of urine by centrifugation (unconcentrated
urine yielded 59 of 139 (42.4 %) diagnoses, whereas con-
centrated urine yielded 82 of 139 (59.0 %) diagnoses; P =
0.006). Overall, 64.0 % (89 of 139) of all cases could be di-
agnosed from urine. In contrast, only 39 (28.1 %) cases
could be diagnosed by Xpert testing sputum (Fig. 2a)
(P <0.001), reflecting in large part the small proportion of
patients able to produce sputum in the first 24 h of admis-
sion. Combined urine and sputum Xpert results gave the
greatest diagnostic yield, detecting 108 of 139 (77.7 %)
cases (Table 5).
The diagnostic yield obtained from urine but not spu-
tum was associated with the CD4 cell count. In those
with CD4 cell counts >100 and ≤100 cells/μL, the pro-
portions diagnosed from sputum were similar (29.7 %
versus 25.7 %, respectively; P = 0.70) whereas the yield
from Xpert testing urine was substantially greater
among those with lower CD4 cell counts (50.0 % versus
77.0 %, respectively; P = 0.001) (Fig. 2b,c).
Diagnostic yield from total clinical samples collected
during admission
We next compared the diagnostic yield from Xpert tests
done on admission urine samples (n = 418) with the
yield from all other samples (615 sputum samples and
712 non-respiratory samples) collected during the entire
period of hospital admission (Table 5 and Fig. 3). The
Fig. 1 Flow diagram showing the study population
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yield from Xpert testing urine was slightly greater (but
this did not reach statistical significance) than that ob-
tained from the combined yield from Xpert and culture
tests done on sputum samples (64.0 % versus 54.0 %, re-
spectively; P = 0.146), but did exceed that from cultures
of other non-respiratory samples (64.0 % vs 50.4 %, re-
spectively; P = 0.028) (Fig. 3a).
Of 75 total microbiologically confirmed pulmonary TB
(PTB) diagnoses, more than one half (n = 42; 56.0 %)
could alternatively be diagnosed by testing urine with
Xpert. Similarly, of the 70 microbiologically confirmed
extrapulmonary TB (EPTB) diagnoses made using culture
of non-respiratory samples, two-thirds (n = 46; 65.7 %)
could be made by testing urine with Xpert. This
proportion varied by sample type (Table 5). For example,
whereas 78.0 % (32 of 41) of those with positive blood cul-
tures tested urine Xpert positive, only 37.5 % (3 of 8) of
those with culture-confirmed TB meningitis tested urine
Xpert positive.
Specificity of Xpert testing
We finally examined the possibility of false-positive spu-
tum Xpert results in patients previously treated for TB
disease who might potentially have had persistent shed-
ding of non-viable organisms in sputum [21]. A positive
Xpert test from one or more sputum samples was re-
corded in 57 patients with a TB diagnosis. Of these, 50
(88 %) had positive cultures from either sputum or a
Table 2 Patient characteristics
Characteristic All patients Patients with a TB diagnosis Patients without a TB diagnosis P value
(n = 427) (n = 139) (n = 288)
Age (years), median (IQR) 36.1 (28.9–42.4) 33.8 (27.2–39.7) 37.1 (30.0–44.0) 0.008
Female 259 (60.7) 90 (64.8) 169 (58.7) 0.229
New HIV diagnosis on admission 82 (19.2) 34 (24.5) 48 (16.7) 0.055
History of previous TBa 196 (46.1) 50 (36.2) 146 (50.9) 0.005
ART status
ART-naive 177 (41.5) 71 (51.1) 106 (36.8) 0.019
ART interrupted 71 (16.6) 19 (13.7) 52 (18.1)
Current ART use 179 (41.9) 49 (35.3) 130 (45.1)
If currently on ART, treatment duration
(years), median (IQR)
1.6 (0.6–3.6) 1.3 (0.2–2.9) 1.7 (0.6–3.7) 0.157
CD4 cell count (cells/uL) (n = 424)
Median (IQR) cells/μL 149 (55–312) 80 (33–182) 191 (73–392) <0.001
<50 94 (22.2) 53 (38.4) 41 (14.3)
50–99 66 (15.6) 21 (15.2) 45 (15.7)
100–149 53 (12.5) 19 (13.8) 34 (11.9)
150–199 42 (9.9) 16 (11.6) 26 (9.1)
≥200 169 (39.9) 29 (21.0) 140 (49.0)
Haemoglobin levels (n = 421)
Median (IQR) 9.6 (7.7–11.6) 8.4 (6.8–10.2) 10.2 (8.2–12.2) <0.001
No/mild anaemia 144 (34.2) 28 (20.1) 116 (41.1)
Moderate/severe anaemia 277 (65.8) 111 (79.9) 166 (58.9)
Symptoms
Cough ≥2 weeksa 34 (8.0) 18 (13.0) 16 (5.6) 0.008
Sputum productiona 161 (38.3) 51 (37.5) 110 (38.7) 0.808
Current cougha 201 (47.4) 84 (60.9) 117 (40.9) <0.001
Current fevera 63 (14.9) 24 (17.5) 39 (13.6) 0.294
Current night sweatsa 174 (41.0) 73 (52.9) 101 (35.3) 0.001
Current reported weight lossa 189 (44.5) 76 (55.1) 113 (39.4) 0.002
Positive WHO symptom screena 389 (91.5) 134 (97.1) 255 (88.9) 0.005
Data presented are numbers (%) unless otherwise stated. aBetween two and seven values missing. IQR, interquartile range
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Table 3 Tuberculosis (TB) prevalence stratified by patient characteristics and the number needed to screen (NNS) to identify one TB
case in different risk groups
Characteristic Number of TB cases TB prevalence, % (95 % CI) P value NNS (95 % CI)
All patients 139 32.6 (28.1–37.2) - 3.1 (2.7–3.6)
Age (years)
<35 (n = 199) 75 37.7 (30.8–44.6) 0.034 2.7 (2.2–3.2)
≥35 (n = 228) 64 28.1 (22.3–34.4) 3.6 (2.9–4.5)
Gender
Male (n = 168) 49 29.2 (22.4–36.6) 0.260 3.4 (2.7–4.5)
Female (n = 259) 90 34.8 (29.0–40.9) 2.9 (2.4–3.4)
HIV diagnosis
New (n = 82) 34 41.5 (32.1–53.1) 0.055 2.4 (1.9–3.1)
Existing (n = 345) 105 30.4 (25.0–35.1) 3.3 (2.8–4.0)
Previous history of TB
No (n = 229) 88 38.4 (32.1–45.1) 0.005 2.6 (2.2–3.1)
Yes (n = 196) 50 25.5 (19.6–32.2) 3.9 (3.1–5.1)
ART status
Naive (n = 177) 71 40.1 (32.8–47.7) 0.007 2.5 (2.1–3.0)
Any ART exposure (n = 250) 68 27.2 (21.8–33.2) 3.7 (3.0–4.6)
CD4 cell count (cells/μL)
<100 (n = 160) 74 46.3 (38.3–54.3) <0.001 2.2 (1.8–2.6)
100–199 (n = 95) 35 36.8 (27.2–47.4) 2.7 (2.1–3.7)
≥200 (n = 169) 29 17.2 (11.8–23.7) 5.8 (4.2–8.5)
WHO anaemia grade
No/mild anaemia (n = 144) 28 19.4 (13.3–26.9) <0.001 5.2 (3.7–7.5)
Moderate/severe anaemia (n = 277) 111 40.0 (34.3–46.1) 2.5 (2.2–2.9)
Sputum production
No (n = 259) 85 32.8 (27.1–38.9) 0.814 3.0 (2.6–3.7)
Yes (n = 161) 51 31.7 (24.6–39.5) 3.2 (2.5–4.1)
Current cough
No (n = 223) 54 24.2 (18.7–30.4) <0.001 4.1 (3.3–5.3)
Yes (n = 201) 84 41.8 (34.9–48.9) 2.4 (2.0–2.9)
Cough duration
<2 weeks (n = 389) 120 30.8 (26.3–35.7) 0.008 3.2 (2.8–3.8)
≥2 weeks (n = 34) 18 52.9 (35.1–70.2) 1.9 (1.4–2.8)
Current fever
No (n = 360) 113 31.4 (26.6–36.5) 0.294 3.2 (2.7–3.8)
Yes (n = 63) 24 38.1 (26.1–51.2) 2.6 (2.0–3.8)
Current night sweats
No (n = 250) 65 26.0 (20.7–31.9) 0.001 3.8 (3.1–4.8)
Yes (n = 174) 73 42.0 (34.5–49.7) 2.4 (2.0–2.9)
Recent weight loss
No (n = 236) 62 26.3 (20.8–32.4) 0.002 3.8 (3.1–4.8)
Yes (n = 189) 76 40.2 (33.2–47.6) 2.5 (2.1–3.0)
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non-respiratory sample, thereby confirming a current
diagnosis of active TB. Of the remaining seven patients,
four had a history of previous TB treatment but only
one of these had received treatment for TB within the
preceding 3-year period.
Discussion
Using comprehensive clinical sampling, a microbio-
logical diagnosis of TB was made in one in three unse-
lected HIV-positive new medical admissions to this
South African district hospital. Since TB prevalence was
so high and since neither clinical symptoms nor patient
risk factors could be used to reliably predict who did
and who did not have TB, we suggest that a policy of
routine microbiological investigation of all HIV-positive
medical admissions may be justified in this and other
high-burden settings. Urine samples were readily ob-
tained from patients in the first 24 h of admission and
testing these with Xpert was the single investigation that
yielded the greatest number of TB diagnoses, represent-
ing nearly two-thirds of total TB diagnoses. Use of Xpert
to screen sputum samples collected in the first 24 h
Table 3 Tuberculosis (TB) prevalence stratified by patient characteristics and the number needed to screen (NNS) to identify one TB
case in different risk groups (Continued)
WHO symptom screen
Negative (n = 36) 4 11.1 (3.1–26.1) 0.005 9.0 (3.8–32.3)
Positive (n = 389) 134 34.5 (29.7–39.4) 2.9 (2.5–3.4)
Table 4 Multivariable logistic regression of patient characteristics associated with tuberculosis (TB) diagnosis
Characteristic Unadjusted odds ratio P value Adjusted odds ratio P value
Age (years)
≥35 1 0.034 1 0.313
<35 1.55 (1.03–2.33) 1.26 (0.81–1.96)
Gender
Male 1 0.227 1 0.170
Female 1.29 (0.85–1.97) 1.40 (0.87–2.25)
Previous history of TB
Yes 1 0.004 1 0.038
No 1.82 (1.20–2.77) 1.66 (1.03–2.69)
HIV diagnosis
Existing 1 0.059 1 0.744
New 1.62 (0.99–2.66) 0.89 (0.46–1.75)
ART status
Ever received ART 1 0.005 1 0.206
Never received ART 1.79 (1.19–2.70) 1.44 (0.82–2.51)
Sputum production
Yes 1 0.808
No 1.05 (0.69–1.61)
WHO symptom screen
Negative 1 0.002 1 0.068
Positive 4.20 (1.46–12.14) 2.59 (0.85–7.92)
CD4 cell count (cells/μL)
≥200 1 <0.001 1 <0.001
100–199 2.77 (1.56–4.93) 2.32 (1.26–4.26)
<100 4.15 (2.50–6.89) 3.17 (1.81–5.56)
Anaemia severity
No/mild anaemia 1 <0.001 1 0.011
Moderate/severe anaemia 2.77 (1.72–4.47) 1.96 (1.16–3.36)
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provided a substantially lower yield, reflecting the well-
recognized difficulty of obtaining sputum from sick in-
patients, especially when they have not been pre-selected
based on respiratory symptoms. Routine testing of urine
samples with Xpert provides an effective means of rapid
TB diagnosis in this patient population and one that could
readily be implemented wherever the GeneXpert test plat-
form is already being used. Consideration should be given
to routine testing of urine as the initial diagnostic screen
in such patients, and especially in those for whom sputum
production is difficult.
Patients were investigated very thoroughly for TB with
an average of 5.6 tests done on samples obtained from a
median of three anatomic compartments in each patient.
Thus, this is likely to have provided a very reliable esti-
mate of TB prevalence in these unselected patients. Posi-
tive non-respiratory samples indicated extrapulmonary
involvement in a large majority (83 %) of TB cases. In-
deed, disease was frequently disseminated as shown by
positive blood cultures in 30 % of TB patients and the
observation that samples from more than one anatomic
site tested positive for TB in approximately half of all TB
cases (Fig. 3).
The prevalence of TB varied by risk categories but in
none of the stratified groups was the prevalence less
than 10 % (Table 3). Admission symptoms were very
poorly predictive of undiagnosed TB and were not sig-
nificantly associated with TB in multivariable analysis.
Thus, we propose that in such clinical populations, pa-
tients should be investigated for TB regardless of their
symptoms. While multiple studies of unselected out-
patients screened prior to starting ART in South Africa
have reported TB prevalence rates of approximately 20–25
% [18, 22–24], comparable studies of unselected hospital
in-patients are lacking. In Lusaka, Zambia, the prevalence
of sputum culture-positive TB was 27 % among HIV-
positive medical in-patients, but these patients were se-
lected on the basis of ability to produce sputum [25]. In
Table 5 Diagnostic yield of tuberculosis (TB) cases from different sample types and the proportion of diagnoses that could be made
using Xpert testing of urine samples
Sample Number of TB diagnoses Diagnostic yield, % (95 % CI) Number diagnosed
by urine Xpert
Proportion diagnosed by
urine Xperta, % (95 % CI)
All clinical samples 139 100 (97.4–100) 89 64.0 (55.5–72.0)
Samples collected during the first 24 h of admission
Urine
Urine Xpert (unconcentrated) 59 42.4 (34.1–51.1) 59 -
Urine Xpert (concentrated) 82 59.0 (50.3–67.3) 82 -
Urine Xpert (either sample) 89 64.0 (55.5–72.0) 89 -
Sputum
Xpert (first sample only) 37 26.6 (19.5–34.8) 20 54.1 (36.9–70.5)
Xpert (either sample) 39 28.1 (20.8–36.3) 20 51.3 (34.8–67.6)
Sputum and urine
Xpert (all samples) 108 77.7 (69.8–84.3) 89 82.4 (73.9–89.1)
All other samples collected during admission
Sputum
Xpert 57 41.0 (32.7–49.7) 30 52.6 (39.0–66.0)
Culture 58 41.7 (33.4–50.4) 33 56.9 (43.2–69.8)
Either culture or Xpert 75 54.0 (453–62.4) 42 56.0 (44.1–67.5)
Cultures of non-respiratory samples
All non-respiratory samples 70 50.3 (41.8–58.9) 46 65.7 (53.4–76.7)
Blood 41 29.5 (22.1–37.8) 32 78.0 (62.4–89.4)
Pleural fluid 13 9.4 (5.1–15.5) 6 46.2 (19.2–74.9)
Urine 11 7.9 (4.0–13.7) 8 72.7 (39.0–94.0)
Cerebrospinal fluid (CSF) 8 5.8 (2.5–11.0) 3 37.5 (8.5–75.5)
Lymph node fine needle aspirate (FNA) 6 4.3 (1.6–9.2) 4 66.7 (22.2–95.7)
Other 5 3.6 (1.2–8.2) 4 80.0 (28.4–99.5)
aAny positive result from testing unconcentrated and concentrated samples
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the absence of a microbiological diagnosis, some patients
might have received empirical TB treatment. However,
since presentation was so very non-specific, such a strategy
would inevitably miss many cases and TB treatment would
be unlikely to be started within the first 24 h of admission.
Only approximately one third of all patients could pro-
duce a sputum sample within 24 h of admission despite
assistance from a dedicated study respiratory nurse and
availability of sputum induction [26]. Just over one half
could produce sputum at any time during admission and
this was strongly related to the presence or absence of re-
spiratory symptoms at the time of admission. Thus, the
low yield from sputum was directly related to the fact that
patients were investigated for TB without pre-selection ac-
cording to respiratory symptomatology. However, in a pre-
vious study of unselected HIV-positive ambulatory out-
Fig. 2 Tuberculosis (TB) diagnoses made by Xpert from urine and sputum samples collected in the first 24 h of hospital admission. Venn diagrams
show diagnostic yields as proportions of (a) total TB diagnoses (n = 139), (b) TB diagnoses in patients with CD4 cell counts >100 cells/μL (n = 64) and
(c) TB diagnoses in patients with CD4 cell counts ≤100 cells/μL (n = 74). Note: the CD4 cell count result was missing for one patient with TB
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patients in this setting, the same research nurse using the
same protocol obtained sputum from 90 % of patients at a
single clinic visit [18, 26]. This also illustrates the well-
recognized difficulties in obtaining sputum from hospital
in-patients who are often too sick, weak or unable to co-
operate. Thus, the very high comparative yield of urine-
based TB diagnostics in this study was in large part a direct
result of the ease with which urine could readily be obtained.
Prior centrifugation of between 30 ml and 40 ml of
urine substantially increased the yield of cases and this
observation is explained by the fact that Xpert detects
the DNA associated with whole M. tuberculosis bacilli,
which sediment with centrifugation, rather than detecting
free DNA [27, 28]. The detection of M. tuberculosis bacilli
in urine is strongly suggestive of renal involvement with
TB, most likely arising as a result of haematogenous dis-
ease dissemination. The yield from urine was substantially
greater among those with lower CD4 cell counts (Fig. 2b,c),
likely reflecting higher mycobacterial load and greater risk
of disease dissemination and renal involvement. Our find-
ings are entirely consistent with a study from the USA
early in the HIV epidemic, which reported a very high
Fig. 3 Yields of total tuberculosis (TB) diagnoses from all clinical samples collected at any time during hospital admission. Yields of TB diagnoses
made by testing urine samples (using Xpert) collected on admission compared with the yield from all sputum samples (using either Xpert and/or
culture) and all other non-respiratory samples (using culture). Venn diagrams show yields as proportions of (a) all TB diagnoses (n = 139), (b) TB
diagnoses in patients with CD4 cell counts >100 cells/μL (n = 64) and (c) TB diagnoses in patients with CD4 cell counts ≤100 cells/μL (n = 74).
Note: the CD4 cell count result was missing for one patient with TB
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yield (77 %) of diagnoses from culture of urine samples
from HIV-infected patients with advanced immunodefi-
ciency and extrapulmonary TB [29]. However, compared
to culture, which may take several weeks, Xpert testing
takes just 2 h. The Determine TB-LAM urine lateral-flow
assay for lipoarabinomannan is an alternative urine-based
rapid TB diagnostic that has shown promise [30]. Al-
though the diagnostic yield is lower than that of urine
Xpert [16], its potential use at the point-of-care and the
lack of need for instrumentation or electricity supply and
its low cost are all very considerable advantages [30].
Xpert testing of urine could be used as a rapid screen-
ing investigation for TB among HIV-infected adults ad-
mitted to medical wards in high-burden settings. The
optimum diagnostic algorithm for a given setting will
depend on the disease burden and the financial re-
sources and infrastructure available. In South Africa, a
single Xpert cartridge is allocated per patient under na-
tional implementation. The greatest overall diagnostic
yield in this clinical population would be obtained from
testing concentrated urine samples and, if used to rou-
tinely screen all HIV-infected patients, approximately
one in five tests would be positive. To gain the increased
yield derived from sample centrifugation, testing would
have to be laboratory-based and with appropriate bio-
safety facilities. Use of urine as the initial diagnostic
sample might reduce the need to obtain respiratory and
other non-respiratory samples. The advantages of this
approach would include reducing the generation of in-
fectious bio-aerosols in the ward environment, decreas-
ing the need for biohazardous sputum induction or the
need for invasive procedures to sample extra-pulmonary
disease sites and reducing requirements for culture. Im-
portantly, urine-based TB diagnosis identifies patients
with the highest mortality risk [15, 16, 31, 32]; expediting
TB diagnosis and treatment in this group may potentially
improve survival. The impact of this screening strategy on
survival and clinical outcomes is being evaluated in a large
randomized controlled trial in South Africa and Malawi
(Rapid urine-based Screening for Tuberculosis to reduce
AIDS-related Mortality in hospitalized Patients in Africa
(STAMP) trial; ISRCTN71603869).
Strengths of the present study include the investiga-
tion of an unselected sample of HIV-infected patients re-
gardless of respiratory symptoms or clinical suspicion of
TB or ability to produce a sputum sample. Microbio-
logical investigation for TB was extremely thorough,
testing a very large number of samples using quality-
assured laboratories. Xpert has been demonstrated to
have very high specificity when testing both respiratory
and non-respiratory samples [12–14]. However, we care-
fully assessed the possibility of false-positive Xpert tests
occurring among patients previously treated for TB and
shedding non-viable organisms in sputum as being very
low in this patient population. We also used single-use
sterile receptacles for urine collection to reduce any risk
of cross-contamination of urine samples with either live
or dead M. tuberculosis bacilli.
Weaknesses include the fact that the study was con-
ducted at a single site and the extent to which these
findings can be generalized to other settings remains to
be assessed. However, the remarkable uniformity in the
findings of autopsy studies of HIV-infected in-patients
conducted in West, East and southern Africa [2–7] and
in India [33] suggest that these findings are likely to be
broadly relevant across high-burden settings. The re-
sults should not be generalized to HIV-infected medical
out-patients in whom the diagnostic yield is known to
be lower [15].
Conclusion
In conclusion, this study has defined a means of rapid
microbiological diagnosis of HIV-associated TB through
systematic screening in newly admitted HIV-positive med-
ical in-patients in high TB burden settings. This urine-
based approach overcomes the frequent difficulties in
obtaining sputum samples from such patients. In addition
to sputum testing, routine testing of urine samples with
Xpert should be considered and further evaluated either as
a first-line screening investigation to enhance the yield and
speed of TB diagnosis in this clinical population or as an
adjunctive investigation in patients who are sputum-scarce.
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